3.239.76.25
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-

Conference Roundup

Long-term benefits of maralixibat in PFIC demonstrated in 2-year study

Maralixibat (MRX) demonstrates significant and sustained improvements in pruritus, serum bile acids (sBA), total bilirubin (TB), and growth in patients with progressive familial intrahepatic cholestasis (PFIC) over a 2-year period, according to a study presented at The Liver Meeting 2023. The study suggests that MRX treatment contributes to overall improved...

Read More
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-